(Q40479170)

20 September 2017

VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. (English)

1 reference

20 September 2017

0 references

1 reference

Jiabin An

1

1 reference

20 September 2017

Myrna Fisher

series ordinal

2

1 reference

20 September 2017

Matthew B Rettig

series ordinal

3

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

20 September 2017

1 reference

20 September 2017

24

1 reference

20 September 2017

1563-1570

1 reference

20 September 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1208348

20 September 2017

0 references

cites work

Series introduction: the transcription factor NF-kappaB and human disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Therapeutic options in the management of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Tumour suppression by the human von Hippel-Lindau gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

The proteasome--an emerging therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

The biological treatment of renal-cell carcinoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

The genetic basis of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208348

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.ONC.1208348

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference